Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

被引：0
|
作者：
Mehmet Akce
Anthony El-Khoueiry
Sarina A. Piha-Paul
Emeline Bacque
Peng Pan
Zhi-Yi Zhang
Reginald Ewesuedo
Divya Gupta
Yongqiang Tang
Ashley Milton
Stefan Zajic
Patricia L. Judson
Cindy L. O’Bryant
机构：
[1] Winship Cancer Institute of Emory University,
[2] University of Southern California Norris Comprehensive Cancer Center,undefined
[3] University of Texas MD Anderson Cancer Center,undefined
[4] GlaxoSmithKline,undefined
[5] EQRx,undefined
[6] Dyne Therapeutics,undefined
[7] Mersana Therapeutics,undefined
[8] GlaxoSmithKline,undefined
[9] University of Colorado Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 88卷
关键词：
Niraparib; Pharmacokinetics; Safety; Dosing; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：825 / 836
页数：11
相关论文
共 50 条
  • [21] Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
    Gupta, Samir K.
    Kantesaria, Bhavna
    Wang, Zaiqi
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (10): : 1283 - 1291
  • [22] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment<bold> </bold>
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. BLOOD, 2013, 122 (21)
  • [23] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Chevalier, Clemence
    Dubourg, Julie
    Bolze, Sebastien
    Fouqueray, Pascale
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 485 - 490
  • [24] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Clémence Chevalier
    Julie Dubourg
    Sébastien Bolze
    Pascale Fouqueray
    [J]. Clinical Pharmacokinetics, 2021, 60 : 485 - 490
  • [25] STEADY-STATE PHARMACOKINETICS OF IDEBENONE IN PATIENTS WITH MODERATE HEPATIC IMPAIRMENT
    COTO, V
    OLIVIERO, U
    SORRENTINO, P
    COCOZZA, M
    DEPAOLA, P
    LINGETTI, M
    [J]. ARCHIVES OF GERONTOLOGY AND GERIATRICS, 1992, 15 (03) : 207 - 214
  • [26] Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
    Song, I. H.
    Ilic, K.
    Wu, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 792 - 792
  • [27] Pharmacokinetics and Safety of Vilazodone in Hepatic Impairment
    Boinpally, Ramesh
    Henry, Dahlia
    Gupta, Samir
    Edwards, John
    Longstreth, James
    Periclou, Antonia
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (04) : 269 - 277
  • [28] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
  • [29] Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment
    Kang, Yue
    Li, Yi
    Xu, Fengyan
    Zhang, Jing
    Wang, Kun
    Chen, Yuancheng
    Wu, Jufang
    Guo, Beining
    Zhang, Yingyuan
    Pharm, B.
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (03) : 505 - 517
  • [30] Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment
    Ouwerkerk-Mahadevan, Sivi
    Halabi, Atef
    Cieslarova, Blanka
    Aerts, Indra
    Witek, James
    van Solingen-Ristea, Rodica
    Luo, Donghan
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (10): : 1147 - 1156
12345